Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes KYV-101, a fully human, autologous chimeric antigen receptor (CAR) T-cell therapy with properties well suited for use in B cell-driven autoimmune diseases and KYV-201, a fully human, allogeneic CAR T-cell therapy.  

By offering more than one mechanism for taming autoimmunity, and with patients currently in treatment for multiple indications in the U.S. and Europe, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

Vida Ventures

Westlake Village BioPartners

The Argentum Group

CAM Capital

LYFE Capital

RTW Investments

Gilead Sciences

Hudson Bay Capital Management

Insight Partners

Intellia Therapeutics

Bain Capital Life Sciences

Northpond Ventures

GordonMD Global Investments

Kyverna Therapeutics

Ingenui-T uses whole blood from a standard draw, providing a less-invasive alternative to apheresis and offering an improved vein-to-vein experience to patients in need. Our CEO Peter Maag, PhD, and CTO Karen Walker share more about our CAR T #celltherapy, the recent FDA's fast-track clearance of KYV-101 to treat multiple sclerosis, and the priority to establish relationships with CAR T centers with Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD.

#celltherapy #autoimmunediseases

https://lnkd.in/evCJaKDD

Dr. Borie, President, R&D and Dr. Chung, CMO shared the stage with several industry veterans in Silicon Valley this week to discuss the advancements in CAR T-cell therapy and our commitment to patient care. Thank you PMWC - Precision Medicine World Conference for the opportunity to spread the excitement!

#cartcelltherapy #autoimmunediseases #trailblazers

https://www.pmwcintl.com

Ingenui-T is our novel, proprietary method to manufacture chimeric antigen receptor (CAR) T cells from a single whole blood draw, thereby improving patient experience, and their caregivers. Read more about it in the BioRxiv article published today:

https://lnkd.in/eudXgcMx

Apheresis presents challenges with its lengthy and invasive procedure. The high demand for apheresis beds, limited capacity, and resource constraints at collection centers further complicate the process. Kyverna's method addresses these challenges, marking a significant advancement in streamlining the patient experience.

 #cartcelltherapy #autoimmunedisease

https://lnkd.in/eV_XeJWm

As CAR T-cell therapies expanded into the autoimmune space, it was great to be able to present Phacilitate in Miami, FL last week our innovative approaches to change the treatment paradigm.

#cartcelltherapy #autoimmunediseases #Advancedtherapies

 https://lnkd.in/evk77ci7

Kyverna is developing #cartcelltherapy that aims to reset the immune system and provide new hope to individuals suffering from autoimmune conditions, with a focus on #rheumatology and #neurology, by leveraging a patient-centric approach.

Speaking with Xtalks, CEO Peter Maag shares Kyverna's focus on #autoimmunedisease and a vision for the future of autoimmune treatment that could make a tangible difference in patients’ lives.

https://lnkd.in/eXHi5FjB

Our investigational #cartcelltherapy, KYV-101, has received fast track designation from #FDA for use in #multiplesclerosis patients. This marks a significant step forward in our mission to change the paradigm in #autoimmunedisease treatment.

https://lnkd.in/e5hPcJtJ

Our President of R&D, Dominic Borie, M.D., Ph.D., and our CMO, James Chung, are speaking at the #PMWC24 2024 Precision Medicine World Conference in Santa Clara this January 24 and will share more insights on how Kyverna is committed to developing #cartcelltherapy for patients living with #autoimmunedisease. With multiple patients treated for multiple indications at various sites across the world, we believe in shifting the treatment paradigm for serious rheumatological and neuro-immunological autoimmune conditions. 

https://lnkd.in/eb9jkcuz

We're excited to have James Chung, CMO, and Tom Van Blarcom, Senior Vice President and Head of Research, represent Kyverna Therapeutics at Phacilitate.

Join us as James discusses "KYV-101: a Fully Human Autologous CAR T-Cell Therapy for Autoimmune Diseases", and Tom presents on "Kyverna Therapeutics: Transformative Outcomes With Autologous CAR T-Cell Therapy for Autoimmune Diseases.”  

Learn more at https://lnkd.in/evk77ci7

#celltherapy #autoimmunediseases

Our Investigational New Drug application for KYV-101 has received FDA clearance for patients with treatment-refractory progressive #multiplesclerosis, enabling a new therapeutic option that can potentially result in sustained treatment-free remission and alleviate risks of long-term toxicities.

#celltherapy #cart #biopharma

https://lnkd.in/e7UbvFia

Our warmest wishes of the Season to everyone dedicated to changing the paradigm in the treatment of autoimmune diseases.
#cartcelltherapy #autoimmunedisease

IPhone / Mobile Compatible

Viewport Meta

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Maps

Content Delivery Network

WordPress

President and CEO

Dominic Borie

Co-Founder and Chief Scientific Officer

Jeffrey Greve

Vice President, Immunology

Charles Kaplan

Vice President, Business Development

Julia Winter

VP Corporate Strategy & Finance

Ryan Jones

Senior Vice President, Head of Research

Tom Van Blarcom

Director Talent Acquisition

Ania Erdogan

Associate Director

Ashley Mahne

Director, Process Development

Daniel Anaya

Marketing and Product

Filiberto de Cal

Heba Nowyhed

Desmond Padhi

Chris Liu

Mark Genovese

Brian L. Kotzin

Daniel Spiegelman

Ian Clark

Karen Walker

Chief Technical Officer

Peter Maag

Chief Executive Officer

Biotechnology Public Companies With Fewer Than 100 Employees

Companies With More Than 50 Employees (Top 10K)

Western US Companies With Less Than $10M in Revenue (Top 10K)

West Coast Companies With More Than 50 Employees (Top 10K)

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Series B - Kyverna Therapeutics

Series A - Kyverna Therapeutics

Computer and Software Services and Scientific Services

Berkeley

California

United States

North America

Kyverna Therapeutics price target lowered by $1 at H.C. Wainwright, here's why

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Kyverna Therapeutics anounces patient data on KYV-101

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

Kyverna Therapeutics GAAP EPS of -$0.67

An autologous anti-CD19 CAR T-cell therapy targeting B-cell driven autoimmune diseases.

An allogeneic anti-CD19 CAR T-cell therapy designed for B-cell driven autoimmune diseases with improved tolerability.

Clinical trials for autoimmune diseases including lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.

A program for patients to access investigational treatments outside of clinical trials under certain conditions.

A therapeutic approach using engineered T cells to potentially reset the immune system and achieve sustained remission.

Hong Kong

Asia

United Kingdom

Europe

Philippines

Switzerland

Director

Principal Scientist

Staff Scientist

Senior Scientist

Associate Scientist - Postdoctoral Fellow

Postdoctoral Scholar

PhD student

Senior Director of Clinical Operations

Director of Clinical Operations

Vice President Clinical Operations

Vice President Global Clinical Operations

Director Clinical Operations (US)

Associate Director of Clinical Operations

Clinical Project Manager

Clinical Research Associate

Data Manager

Group Claims Examiner

Cell and Gene Therapy, Clinical Operations

Shannon Inman

Associate Director of Project Management

Sr. Project Manager, Clinical Operations

Medical Operations Consultant

Senior Manager, Global Medical Operations

Medical and Scientific Operations Sr. Operations Associate

Clinical Trial Assistant

Lead Reimbursement Representative

Patient Account Representative

Program/Project Manager , Clinical Project Manager

Curtis Murray-Thorup

Director, External Manufacturing

CMC Lead

Associate Director, External Manufacturing

Associate Director, Commercial Operations

Senior Manager, Cell Therapy Manufacturing Operations

Manager, Cell Therapy Manufacturing Operations

Clinical Trials Operations Manager, Cellular Therapeutics

Project Manager II

Manager, Cell Therapy Process Development

Manager

Senior Research Associate

Manufacturing Associate

Director, External Manufacturing at Kyverna Therapeutics

Jennifer Adrian

Head Of Human Resources

Regional VP/Director, Human Resources Business Partner

HR Business Partner

HR/Administration Manager

Senior HR Business Partner

HR Leader - Inspire human brilliance

Penny Wong

Director Patient Operations

Cell&Gene Therapy Medical Lead Austria

Cell Therapy Medical Manager

Medical Advisor Hematology

Scientific Advisor

Scientific Project Manager

Senior Post Doctoral Fellow

Cell Therapy | CAR-T | Medical Affairs Professional | Patient Operations

Katherine Wachmann

Vice President, External R&D

Associate Group Medical Director

Global Development Team Leader

Senior Medical Director - Product Development Immunology

Senior Medical Director - US Medical Affairs

Medical Director - Global Development Leader

Clinical Research Medical Director, Global Development

Director, Early Development

Director, Translational medicine

Director, Transplantation Research

Director, Transplantation Immunology

Attending Liver Transplant Surgeon

President, Research & Development at Kyverna Therapeutics

Executive Director

Executive Director at Kyverna Therapeutics

Heather Hughes

Associate Director, Manufacturing Sciences & Technology

Senior Process Engineer

Supply Chain Analyst

Manufacturing Manager

Lead Manufacturing Associate

CRISPR/Cas9 Development Associate

Hybridoma Manufacturing Technician

Laboratory Technician

Research Intern

Intern

Director, Process Development at Kyverna Therapeutics

Director, Program Management

Associate Director, Program Management

Associate Director, R&D Project Management

Project Manager and Team Leader

Project Manager, Medicine and Process Delivery

Upstream Process Development Intern

Director, Program Management at Kyverna Therapeutics

Luke Badalaty

Associate Director of Quality Control

Associate Director Quality Control

Analytical Development Manager / Scientist

Analytical Development

Quality Control Scientist

QC analyst III

Cell Therapy Specialist III

Quality Control Associate

Quality Control Associate II

Lab technician

Quality Control/Analytical Development

Mario Lorente

news impact assignment basic	general
public peers	general
news daily refresh	general	Aug 6, 2024 9:00 PM	9511fe69
news processing daily refresh	general	May 21, 2024 3:01 AM	161fd3bb
news impact assignment daily	general	May 21, 2024 4:25 PM	2a3f14df
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	9051e5bb
crunchbase profile	general	Nov 27, 2024 1:26 PM	296c0cb7
li profile	general	Feb 2, 2024 2:15 PM	a6bfe739
translate crunchbase fundingrounds	general	Nov 27, 2024 2:58 PM	18db4f25
peers	general	Feb 2, 2024 2:15 PM	126ca9a1
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

KYTX

COM:KYVERNATX

Kyverna TX

Last Close

3.99

22/11 21:00

Market Cap

364.75M

Beta: -

Volume Today

269.18K

Avg: -